WB
H M R
Endogenous
58
Rabbit
#P14373
5987
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat
Species predicted to react based on 100% sequence homology
The antigen sequence used to produce this antibody shares
100% sequence homology with the species listed here, but
reactivity has not been tested or confirmed to work by CST.
Use of this product with these species is not covered under
our
Product Performance Guarantee.
Monkey, Bovine
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu255 of human TRIM27 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Tripartite motif containing protein 27 (TRIM27, RFP) is a member of the tripartite motif (TRIM) family whose members contain a RING domain, a B-box, and a coiled-coil region (together called RBCC). TRIM27 was originally discovered as part of an oncogenic DNA rearrangement resulting in a fusion of the amino terminal RBCC region of TRIM27 with the carboxyl terminal kinase domain of the receptor tyrosine kinase Ret (1). Overexpression of TRIM27 induces JNK and p38 MAPK activation as well as apoptosis (2). TRIM27 has been found to have pleiotropic effects including transcriptional repression (3,4), and E3 ligase activity for ubiquitin (5-7), and SUMO (8). TRIM27 was originally found to interact with Enhancer of Polycomb (EPC) and function as a transcriptional repressor (3). Subsequent studies have identified ubiquitin E3 ligase activity in TRIM27 as well as other members of the TRIM family (reviewed in 9). Potential substrates of TRIM27-mediated ubiquitination include class II PI3K-C2β, NOD2, and WASH. Elevated expression of TRIM27 has been observed in several types of cancer, where in some cases it may be a predictor of poor prognosis (10-13).
- Takahashi, M. et al. (1988) Mol Cell Biol 8, 1853-6.
- Dho, S.H. and Kwon, K.S. (2003) J Biol Chem 278, 31902-8.
- Shimono, Y. et al. (2000) J Biol Chem 275, 39411-9.
- Bloor, A.J. et al. (2005) Oncogene 24, 6729-36.
- Cai, X. et al. (2011) Proc Natl Acad Sci U S A 108, 20072-7.
- Zurek, B. et al. (2012) PLoS One 7, e41255.
- Hao, Y.H. et al. (2013) Cell 152, 1051-64.
- Chu, Y. and Yang, X. (2011) Oncogene 30, 1108-16.
- Meroni, G. and Diez-Roux, G. (2005) Bioessays 27, 1147-57.
- Tezel, G.G. et al. (2009) Pathol Res Pract 205, 403-8.
- Tsukamoto, H. et al. (2009) Cancer Sci 100, 1895-901.
- Iwakoshi, A. et al. (2012) Pathol Int 62, 324-30.
- Zoumpoulidou, G. et al. (2012) J Natl Cancer Inst 104, 941-52.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
